Dicerna adds to a Series B funding round, resulting in $29M

10/21/2010 | Mass High Tech (Boston)

Dicerna Pharmaceuticals has obtained $29 million from a Series B funding round after securing an additional $4 million from a second close. Dicerna CEO Doug Fambrough relaunched the round because of "significant additional interest from the investment community in our unique Dicer Substrate Technology platform and next generation approach to developing RNAi therapeutics," according to a news release.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR